Furthermore, while Canadians are being denied timely access to new major pharmaceuticals, they are also having difficulty getting access to natural and complementary health products.

A complementary approach that both promotes the principle of better regulation and ensures a high level of protection can be achieved where the products made by the manufacturers of optical radiation sources and associated equipment comply with harmonised standards devised to protect the health and safety of users from the hazards inherent in such products; accordingly, it is not necessary for employers to repeat the measurements or calculations already undertaken by the manufacturer to determine compliance ...[+++] with the essential safety requirements of such equipment as specified in the applicable Community Directives, provided that the equipment has been properly and regularly maintained.

1. Where a Member State, as a result of new or additional information made available since the date of the consent and affecting the environmental risk assessment or reassessment of existing information on the basis of new or additional scientific knowledge, has detailed grounds for considering that a GMO as or in a product which has been properly notified and has received written consent under this Directive constitutes a risk to human health or the environment, that Member State may provisionally restrict or prohibit the use and/or ...[+++]sale of that GMO as or in a product on its territory.

1. Where a Member State, as a result of new or additional information made available since the date of the consent and affecting the environmental risk assessment or reassessment of existing information on the basis of new or additional scientific knowledge, has detailed grounds for considering that a GMO as or in a product which has been properly notified and has received written consent under this Directive constitutes a risk to human health or the environment, that Member State may provisionally restrict or prohibit the use and/or ...[+++]sale of that GMO as or in a product on its territory.

IVCOMMUNITY ACTION PROGRAMME IN THE FIELD OF PUBLIC HEALTH PAGEREF _Toc502054161 \h IV(2001 2006) PAGEREF _Toc502054162 \h IVHEALTH AND NUTRITION Resolution PAGEREF _Toc502054163 \h IVTOBACCO PAGEREF _Toc502054164 \h VI?Directive on tobacco advertising PAGEREF _Toc502054165 \h VI?Manufacture, presentation and sale of tobacco products PAGEREF _Toc502054166 \h VII?World Health Organisation (WHO) Framework Convention on Tobacco Control PAGEREF _Toc502054167 \h VIIPAEDIATRIC MEDICINAL PRODUCTS - Resolution PAGEREF _Toc502054168 \h VIIACTION PLAN "e-EUROPE 2002 AN INFORMATION SOCIETY FOR ALL" PAGEREF _Toc502054169 \h VIIIGOOD CLINICAL PRACTIC ...[+++]E IN THE CONDUCT OF CLINICAL TRIALS ON MEDICINAL PRODUCTS FOR HUMAN USE PAGEREF _Toc502054170 \h VIIICOMMUNICABLE DISEASES PAGEREF _Toc502054171 \h IX?ESTABLISHMENT OF A EUROPEAN MONITORING AND RAPID RESPONSE NETWORK PAGEREF _Toc502054172 \h IX?BSE AND the EPIDEMIOLOGICAL SITUATION OF VARIANT CREUTZFELDT-JAKOB Conclusions PAGEREF _Toc502054173 \h IXPRESENTATION OF NEW TEXTS BY THE COMMISSION PAGEREF _Toc502054174 \h X?COUNCIL RECOMMENDATION ON "DRINKING OF ALCOHOL BY CHILDREN AND ADOLESCENTS" PAGEREF _Toc502054175 \h X?DIRECTIVE ON BLOOD PRODUCTS PAGEREF _Toc502054176 \h XOTHER BUSINESS PAGEREF _Toc502054177 \h XI?THE EUROPEAN APPROACH TO THERAPEUTIC TRIALS CONCERNING AIDS PAGEREF _Toc502054178 \h XIITEMS DISCUSSED OVER LUNCH PAGEREF _Toc502054179 \h XIITEMS APPROVED WITHOUT DEBATEEXTERNAL RELATIONS PAGEREF _Toc502054180 \h XI--South Ossetia Small arms PAGEREF _Toc502054181 \h XI--Albania PAGEREF _Toc502054182 \h XI--Lithuania PAGEREF _Toc502054183 \h XII--Algeria PAGEREF _Toc502054184 \h XII--Relations with the ACP States PAGEREF _Toc502054185 \h XIITRADE POLICY PAGEREF _Toc502054186 \h XIII--Anti-dumping Sacks and bags made of polyethylene or polypropylene (India) PAGEREF _Toc502054187 \h XIIIECOFIN PAGEREF _Toc502054188 \h XIII--Euro bank notes and coins - conclusions (additional) PAGEREF _Toc502054189 \h XIII--Single facility pro ...

The European Commission decided to approve the acquisition by Alliance Uncihem, through its French subsidiary Alliance Santé, of Safa Galenica. Unichem is a leading European pharmaceutical wholesaler, especially active in the UK, France, Italy and Portugal.